Regulus Therapeutics Inc - 92121 San Diego, CA

Business Name: Regulus Therapeutics Inc
Categorized In:
Address: 3545 John Hopkins Court # 210, San Diego, CA 92121
Phone Number: (858) 202-6300
Contact Person: Kleanthis Xanthopoulos, Chief Executive Officer
Website Address: regulusrx.com
NAICS Code: 5417112
SIC Code: 2834
Business Type: B2B & B2C
Founding Year: 2007
Employee #: 1 to 4
Location Type: Headquarters
Annual Revenue ($): Unknown
Share This Business:
Similar Businesses: Tioga Pharmaceuticals Inc - San Diego, CA 92121
Amplyx Pharmaceuticals Inc - San Diego, CA 92121
Depotech Corp - San Diego, CA 92121
Pacira Pharmaceuticals Inc - San Diego, CA 92121
Amylin Ohio LLC - San Diego, CA 92121
Conatus Pharmaceuticals Inc - San Diego, CA 92121
Novomedix - San Diego, CA 92121
Coda Therapeutics Inc - San Diego, CA 92121
Bioserv Corp - San Diego, CA 92121
Proprius Inc - San Diego, CA 92121
Arena Pharmaceuticals Inc - San Diego, CA 92121
Amaze Therapeutics - San Diego, CA 92121
Mirati Therapeutics - San Diego, CA 92121
Formex LLC - San Diego, CA 92121
Prometheus Rxdx Inc - San Diego, CA 92121
Neuropore Therapies - San Diego, CA 92121
Skyepharma Inc - San Diego, CA 92121
Phage Biotechnology Corporation - San Diego, CA 92121
Advanced Molecular Design Inc - San Diego, CA 92121
Epigen Biosciences Inc - San Diego, CA 92121

Regulus Therapeutics Inc provides professional from its headquarters at the coordinates 32.89217,-117.23794.

The company offers BOTH variables under the SIC code 2834 and NAICS code 5417112, while making an annual revenue of Unknown and hiring a total of 1 to 4 employees.

Founded in 2007, the company can now be visited at 3545 John Hopkins Court # 210, San Diego, California 92121 or contacted through representative Kleanthis Xanthopoulos, Chief Executive Officer at (858) 202-6300.

For frequently asked questions and further inquiries about professional , get to know more about Regulus Therapeutics Inc through its company website at regulusrx.com. Engage with this business on its social media platforms through on Twitter and on Facebook.